https://www.selleckchem.com/pr....oducts/carfilzomib-p
nistered dose; in feces, parent drug was about 8.61% of the dose administered and HAS-719 was the major metabolite, accounting for 12.33% of the administered dose, which was followed by M541a/M470a and M617/M575, accounting for 11.8% and 6.76% of the administered dose, respectively. Almonertinib has a good safety profile, with parent drug as its main circulating component. almonertinib is extensively metabolized before excretion and is excreted as a parent drug and metabolites mainly via feces. The trial registration number C
Synes godt om
Kommentar
Del
